Jasmine Kamboj, Medical Oncologist and Hematologist at Mayo Clinic, Podcast Editor and Host of the “Empowering Oncologists” Podcast at OncoDaily, Recipient of the Yvonne Award 2025 in the “Community Oncology” Category, shared a post on LinkedIn:
“On Jan 27, 2026, CMS published select drug list for next cycle of the ‘Medicare Drug Price Negotiation Program.’
Several cancer drugs are on the list.
- Lenvima,
- Erleada,
- Verzenio,
- Kisqali
As a key stakeholder, your perspective is vital in ensuring patient experience and clinical evidence are fully considered during the CMS process to evaluate the fair price for the drugs.
Please consider sharing your perspective. Thanks Craig Warren for sharing the information!”
More posts featuring Jasmine Kamboj.